Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of stapokibart in allergic rhinitis
CTR20242457Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of stapokibart in allergic rhinitis (AR), sponsored by Keymed Biosciences. Started Oct 2024; status: active.
02
Drugs
stapokibart
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on CTR20242457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242457.